


# PRODUCT INFORMATION



## SU6656

Item No. 13338

**CAS Registry No.:** 330161-87-0  
**Formal Name:** 2,3-dihydro-N,N-dimethyl-2-oxo-3-[[4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide  
**MF:** C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>S  
**FW:** 371.5  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 232, 300, 445 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

SU6656 is supplied as a crystalline solid. A stock solution may be made by dissolving the SU6656 in the solvent of choice, which should be purged with an inert gas. SU6656 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of SU6656 in these solvents is approximately 20 mg/ml.

### Description

The Src family of proto-oncogenic kinases include nine mammalian non-receptor tyrosine kinases that are involved in intracellular signaling and are often relevant to carcinogenesis. SU6656 is a selective inhibitor of Src kinases, including Src, Yes, Lyn, and Fyn (IC<sub>50</sub> = 280, 20, 130, 170 nM, respectively).<sup>1</sup> It weakly inhibits some other kinases when used at >10 μM.<sup>1,2</sup> SU6656 has been used to study the role of Src kinases in cell growth and development in diverse processes, including nervous system development, fibrosis, and cancer.<sup>3-5</sup>

### References

1. Blake, R.A., Broome, M.A., Liu, X., *et al.* SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. *Mol. Cell. Biol.* **20(23)**, 9018-9027 (2000).
2. Bain, J., McLauchlan, H., Elliot, M., *et al.* The specificities of protein kinase inhibitors: An update. *Biochem. J.* **371(Pt. 1)**, 199-204 (2003).
3. Jin, W., Yun, C., Jeong, J., *et al.* c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. *J. Biol. Chem.* **283(3)**, 1391-1400 (2008).
4. Distler, J.H.W. and Distler, O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. *Rheumatology* **47(Suppl 5)**, 10-11 (2008).
5. Fossey, S.L., Liao, A.T., McCleese, J.K., *et al.* Characterization of STAT3 activation and expression in canine and human osteosarcoma. *BMC Cancer* **9:81**, (2009).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/19/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM